Revenue: The sum of all revenue fields included for a company's operating activities.
Halozyme Therapeutics, Inc. (HALO) had Revenue of $325.72M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
|
Revenue |
$325.72M |
$165.16M |
|
$46.36M |
|
$279.36M |
|
$123.28M |
|
$202.44M |
|
$2.50M |
|
$204.94M |
|
$204.94M |
|
$165.16M |
|
$165.16M |
|
$165.16M |
|
$165.16M |
|
$202.44M |
|
$223.66M |
|
121.34M |
|
124.16M |
|
$1.36 |
|
$1.33 |
|
| Balance Sheet Financials | |
$1.12B |
|
$71.52M |
|
$931.23M |
|
$2.05B |
|
$134.28M |
|
$1.51B |
|
$1.59B |
|
$1.72B |
|
$332.75M |
|
$-450.38M |
|
$332.75M |
|
117.62M |
|
| Cash Flow Statement Financials | |
$253.93M |
|
$-5.63M |
|
$-302.29M |
|
$115.85M |
|
$61.86M |
|
$-53.99M |
|
$22.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.36 |
|
-- |
|
-- |
|
0.82 |
|
4.54 |
|
85.77% |
|
62.15% |
|
62.15% |
|
-- |
|
62.92% |
|
50.71% |
|
$251.42M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
0.26 |
|
1.03 |
|
87.41 |
|
49.64% |
|
-36.67% |
|
8.04% |
|
8.97% |
|
$2.83 |
|
$2.02 |
|
$2.05 |
|